SCHEMBL13633926

SCHEMBL13633926

Cc1nc(-c2cc3ccccc3o2)oc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
MAPT P10636 3/20 0.45
MAOB P27338 5/20 0.45
MAOA P21397 3/20 0.45
ADRA2A P08913 2/20 0.44
METAP2 P50579 1/20 0.44
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GRM4 Q14833 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
NISCH Q9Y2I1 1/20 0.43
F2RL3 Q96RI0 1/20 0.43
ALOX5 P09917 1/20 0.42
CD74 P04233 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5789778 0.80 SMN1; SMN2 (0.42) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL3132729 0.75 NPC1 (0.61) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL103158 0.74 MAOB (0.63) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL30036439 0.74 MAOB (0.63) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL3131278 0.74 KDM4E (0.63) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL8982190 0.73 MAOB (0.45) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL8982216 0.72 NPC1 (0.52) NPC1RAB9AMAPTHPGDHSD17B10
SCHEMBL7125503 0.72 MAOB (0.52) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL30561833 0.71 MAOB (0.55) NPC1RAB9AMAPTMAOBMAOA
SCHEMBL2150499 0.71 MAOB (0.59) NPC1RAB9AMAPTMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 NPC1 1894/4885RAB9A 543/4885MAPT 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.